nivolumab,relatlimab
bms
['melanoma', 'nivo', 'improve ']
great educational session on #immunotherapy combos in #melanoma. the role of il il-2 as abscopal effect for anti pd-1 treatment should be further studied to improve m1a response rates (not as high as hoped in the nivo-rela trial) #asco2022 
Medical oncologist, @lemelbaum institute for immuno-oncology. Treating patients with #Melanoma, interested in #Immunotherapy and clinical trials